1.23 USD
▲+0.03+2.50%
2026-08-03
市值
$88.93M
市盈率
—
EPS
-0.73
股息率
—
52 周区间
0.87 – 2.99
成交量
622.59K
Beta
-0.29
目标价
6.83
52W 低 0.8752W 高 2.99
价格走势
公司简介
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for ...